KalVista Pharmaceuticals Reports Q1 Results Amidst Pending $27/Share Acquisition by Chiesi Group
KALV has more than doubled off its 52-week low of $9.83.
Summary
KalVista Pharmaceuticals, Inc. filed its Q1 2026 report, detailing strong revenue growth from EKTERLY sales and a reduced net loss, while confirming its pending acquisition by Chiesi Group for $27.00 per share.
Key Events · M&A and Partnerships · KALV
-
Definitive Acquisition Agreement
KalVista Pharmaceuticals has entered into a definitive agreement to be acquired by Chiesi Group for $27.00 per share in cash. This news was previously announced on April 29, 2026.
-
Tender Offer Launched
Chiesi Group commenced its tender offer on May 13, 2026, to acquire all outstanding shares at the offer price, with the offer set to expire on June 10, 2026.
-
Strong Revenue Growth
The company reported total revenues of $40.9 million for the three months ended March 31, 2026, compared to $0 in the prior-year period, driven by the commercial launch of EKTERLY.
-
Reduced Net Loss
Net loss significantly decreased to $23.5 million for Q1 2026, down from $51.8 million in Q1 2025.
Analysis · KALV · Life Sciences
This quarterly report provides financial updates for KalVista Pharmaceuticals, Inc. for the period ended March 31, 2026, while also reiterating the definitive agreement to be acquired by Chiesi Group for $27.00 per share. The acquisition, announced on April 29, 2026, and with a tender offer launched on May 13, 2026, is the most significant event for the company, effectively setting a near-term ceiling for the stock price. The financial results show continued commercialization of EKTERLY, with significant revenue growth and reduced net loss, but these operational details are now secondary to the pending merger. The stock trading near its 52-week high and close to the offer price indicates the market has largely priced in the acquisition.
At the time of this filing, KALV was trading at $26.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $26.85. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.